NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection

Authors


  • Potential conflict of interest: Dr. Smith is on the speakers' bureau of, consults for, and received grants from Gilead and Vertex. He received grants from Mochida, Abbott, and Jannsen. He received grants from and is on the speakers' bureau of Merck. He is on the speakers' bureau of and consults for Bayer. He also consults for Bristol-Myers Squibb.

No abstract is available for this article.

Ancillary